Treatment оf Osteoporosis in the Context of Fractures Prevention: the Implementation of Data of Evidence-Based Medicine into Clinical Practice. In Focus — Ibandronic Aci

I.Yu. Golovach

Abstract


The article presents the aggregate data about the effectiveness of bisphosphonates in the treatment of osteoporosis. At present, bisphosphonates are most potent modulators of bone metabolism and is the gold standard in treating and preventing osteoporosis. Evidence-based medicine puts a lot of requirements for drugs to treat osteoporosis. First of all, they must reliably prevent the occurrence of vertebral and non-vertebral fractures. These drugs also have a positive influence on bone metabolism and increase the growth of bone mineral density. Duration of the study on bisphosphonates intake is important. Studies duration of which exceeds 3–5 years have probative value. The article analyzed the results of randomized clinical studies of ibandronic acid from the standpoint of vertebral and non-vertebral fractures prevention. So, in BONE randomized clinical trial demonstrated ability of ibandronate in reducing the risk of vertebral fractures by 62 %. Ibandronate in numerous clinical studies have shown high efficacy in preventing bone fractures, increasing bone mineral density of lumbar spine and femur. The drug has a good safety profile, patients has high compliance to long-term treatment due to tablet form of 150 mg to be taken 1 time per month.


Keywords


osteoporosis; bone fractures; bone mineral density; evidence-based medicine; ibandronate

References


Белая Ж.Е., Рожинская Л.Я. Бисфосфонаты: мифы и реальность // Эффективная фармакотерапия в эндокринологии. — 2010. — № 9 (сентябрь). — С. 52-59.

Беневоленская Л.И. Бисфосфонаты в профилактике и лечении остеопороза // Рос. ревматол. — 1998. — № 2. — С. 2-9.

Головач І.Ю. Еволюція бісфосфонатів: сходження на вершину // Мистецтво лікування. — 2009. — № 9–10. — С. 68-74.

Головач І.Ю. Чи всі бісфосфонати однакові? Подібність і відмінність у механізмах дії та потенційний вплив на клінічну ефективність // Рациональная фармакотерапия. — 2010. — № 4. — С. 22-25.

Памидроновая кислота в лечении заболеваний костной ткани / Под ред. В.В. Поворознюка. — К., 2010. — 220 с.

Поворознюк В.В. Бисфосфонаты: роль ибандроновой кислоты в лечении постменопаузального остеопороза // Здоров’я України. — 2007. — № 5. — С. 57-58.

Торопцова Н.В., Никитинская О.А., Беневоленская Л.И. Новый препарат бонвива для лечения постменопаузального остеопороза // Остеопороз и остеопатии. — 2006. — № 2. — С. 42-45.

Blake D.M., Cummings S.R., Karpf D.B. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. FIT Research Group // Lancet. — 1996. — Vol. 348. — P. 1535-1554.

Blake D.M., Delmas P.D., Eastell R. et al. Once-Yearly Zolendronic acid for treatment od postmenopausal osteoporosis // New Engl. J. Med. — 2007. — Vol. 356. — P. 1809-1822.

Bock O., Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis — optimizing efficacy in clinical practice // Clin. Interv. Aging. — 2008. — Vol. 3(2). — P. 279-297.

Chesnut III C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis // J. Bone Miner. Res. — 2004. — Vol. 19. — P. 1241-1249.

Cramer J., Amonkar M.M., Hebborn A. et al. Compliance and persistence with bis-phosphonate dosing regimens among women with postemenopausal osteoporosis // Curr. Med. Res. Opin. — 2005. — Vol. 21. — P. 1453-1460.

Cummings S.R., Blake D.M., Thompson D.E. et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from Fracture International Trial // JAMA. — 1998. — Vol. 280. — P. 2077-2082.

Cummings S.R., Melton III L.J. Epidemiology and outcomes of osteoporosis fractures // Lancet. — 2002. — Vol. 359. — P. 1761-1767.

Delmas P.D., Recker R.R., Chesnut C.H. et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study // Osteoporos Int. — 2004. — Vol. 15. — P. 792-798.

Delmas P.D., Adami S., Strugala C. et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study (DIVA) // Arthritis Rheum. — 2006. — Vol. 54. — P. 1838-1846.

Emkey R., Koltun W., Beusterien K. et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Bonviva Alendronate Trial in Osteoporosis // Curr. Med. Res. Opin. — 2005. — Vol. 21. — P. 1895-1903.

Epstein S., Zaidi M. Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis // Bone. — 2005. — Vol. 37. — P. 433-440.

Felsenberg F., Cooper С., Delmas P.D. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study // Ann. Rheum. Dis. — 2006. — Vol. 65. — P. 654-661.

Fleisch H. Bisphosphonates: mechanisms of action // Endocr. Rev. — 1998. — Vol. 19. — P. 80-100.

Gold D.T., Lyles K.W., Shipp K.M., Drezner M.K. Osteoporosis and its nonskeletal consequences: their impact on treatment decisions. In: Marcus R., Feldman D., Kelsey J., ed. Osteoporosis, 2nd ed. — San Diego: Academic Press, 2001. — P. 479-484.

Hadji P., Benhamou C-L., Devas V. et al. Women with postmenopausal osteoporosis prefer once-monthly oral ibandronate to weekly oral alendronate results of BALTO II. Abstr. Sixth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis // Osteoporos Int. — 2006. — Vol. 17, Suppl. 1. — P. 156.

Hochberg M.C., Greenspan S., Wasnich R.D. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents // J. Clin. Endocrinol. Metab. — 2002. — Vol. 87. — P. 1586-1592.

Johnell O., Kanis J.A., Oden A. et al. Mortality after osteoporotic fractures // Osteoporos Int. — 2004. — Vol. 15. — P. 38-42.

Kanis J.A., Oden A., Johnell O. et al. Excess mortality after hospitalisation for vertebral fracture // Osteoporos Int. — 2004. — Vol. 15. — P. 108-112.

Kanis J.A., Johnell O., Oden A. et al. FRAX™ and the assessment of fracture probability in men and women from the UK // Osteoporos Int. — 2008. — Vol. 19. — P. 385-397.

Melton III L.J., Chrischilles E.A., Cooper C. et al. Perspective. How many women have osteoporosis? // J. Bone Miner. Res. — 1992. — Vol. 7. — P. 1005-1010.

Melton III L.J. Excess mortality following vertebral fracture // J. Amer. Geriatr. Soc. — 2000. — Vol. 48. — P. 338-339.

Meunier P.J., Roux C., Seeman E. et al. The Effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis // New Engl. J. Med. — 2004. — Vol. 350. — P. 459-468.

Miller P.D., McClung M., Macovei I. et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study // J. Bone Miner. Res. — 2005. — Vol. 20. — P. 1315-1322.

Miller P.D., Epstein S., Sedarati F., Reginster J.Y. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study // Curr. Med. Res. Opin. — 2008. — Vol. 24(1). — P. 207-213.

Papapoulos S.E. Ibandronate: a potent new bisphosphonate in the management of postmenopausl osteoporosis // IJCP. — 2003. — Vol. 57. — P. 417-422.

Recker R., Weinstein R., Chesnut III C.H. et al. Long-term treatment with oral daily and intermittent ibandronate produces newly formed bone of normal quality in patients with postmenopausal osteoporosis // Osteopor. Int. — 2003. — Vol. 14 (Suppl. 7). — S73 (Abstr. P265).

Reginster J.Y., Seeman E., Vernejoul M.C. et al. Strontium ranelate reduces the of nonvertebral fractures in postmenopausal women with osteoporosis (TROPOS Study) // J. Clin. Endocrinol. Meta. — 2005. — Vol. 90. — P. 2816-2822.

Reginster J.Y., Wilson K.M., Dumount E. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the Monthly Oral Pilot Study // J. Clin. Endocrinol. Metab. — 2005. — Vol. 90. — P. 5018-5024.

Reginster J-Y., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study // Ann. Rheum. Dis. — 2006. — Vol. 65. — P. 654-661.

Rogers M.J. New insights into molecular mechanisms of action of bisphosphonates // Curr. Pham. Des. — 2003. — Vol. 9. — P. 2643-2658.

Silverman S.L., Maricic M. Recent developments in bisphosphonates therapy // Semin. Arthritis Rheum. — 2007. — Vol. 36. — P. 341-345.

Tanko L.B., McClung M.R., Schimmer R.C. et al. The efficacy of 48-week oral iban dronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast // Bone. — 2003. — Vol. 32(4). — P. 421-426.




DOI: https://doi.org/10.22141/1608-1706.1.14.2013.88874

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 TRAUMA

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru